肺曲霉菌病术后静脉应用不同疗程伏立康唑的疗效观察  

Effect observation of Intravenous voriconazole with different courses of treatment after Pulmonary aspergillosis surgery

作　　者：陈成[1] 宋永祥[1] 徐刚[1] 蔡庆勇[1] 

机构地区：[1]遵义医学院附属医院胸外科,贵州省遵义市563000

出　　处：《临床合理用药杂志》2016年第32期9-10,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察肺曲霉菌病术后静脉应用不同疗程伏立康唑的临床治疗效果。方法 选取医院实施肺曲霉菌病手术后的患者76例作为研究对象,随机分为对照组和观察组,每组38例。观察组给予持续7d静脉滴注伏立康唑治疗,对照组给予持续10-14d静脉滴注伏立康唑治疗,2组临床症状改善后均改为口服伊曲康唑。观察2组患者临床疗效及不良反应发生情况。结果 治疗后,观察组总有效率为94.74%,对照组为92.11%,2组差异无统计学意义（P〉0.05）。观察组不良反应发生率为7.89%,显著低于对照组的31.58%（P〈0.01）。结论 伏立康唑在肺曲霉菌病术后短期使用7d即能达到有效的治疗效果,更安全,无需延长使用时间,因为增加药物使用时间可能带来更多的不良作用。Objective To investigate the clinical efficacy of intravenous voriconazole with different courses of treatment after pulmonary aspergillosis surgery. Methods 76 patients received pulmonary aspergillosis surgery in the hospital were randomly divided into control group and observation group,38 eases in each. The observation group was given consistent 7d intravenous drip of voriconazole, while the control group was given consistent 10 - 14d intravenous drip of vorieonazole. The two groups changed to oral itraeonazole after their clinical symptoms improved. The clinical efficacy and occurrence of adverse reactions of two groups were compared. Results After treatment, The total effective rate of observation group was 94.74%, and the control group was 92.11%, there was no significant difference between the two groups （ P 〉 0.05 ） ; The incidence rate of adverse reactions in the observation group was 7.89% ,which was significantly lower than 31.58% of the control group（ P 〈 0. 01 ）. Conclusion After Pulmonary aspergillosis surgery, the short-term use of voriconazole 7d can reach the therapeutic effect, and more security, there is no need to increase the use of time further, further increase the time of drug use may lead to more side effects.

关 键 词：肺曲霉菌病 伏立康唑 临床疗效 不良反应 

分 类 号：R655.3[医药卫生—外科学]